Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, May 3, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Keay Nakae Reiterated (ABUS) at Strong Buy and Held Target at $4 on, May 3rd, 2024
Keay Nakae of Chardan Capital, Reiterated "Arbutus Biopharma Corporation" (ABUS) at Strong Buy and Held Target at $4 on, May 3rd, 2024.
Keay has made no other calls on ABUS in the last 4 months.
There are 2 other peers that have a rating on ABUS. Out of the 2 peers that are also analyzing ABUS, 0 agree with Keay's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Keay
- Roy Buchanan of "JMP Securities" Reiterated at Buy and Held Target at $4 on, Thursday, April 4th, 2024
- Ed Arce of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $5 on, Friday, March 1st, 2024
